RT Journal Article
SR Electronic
T1 The role of SARS-CoV-2 genomic surveillance and innovative analytical platforms for informing public health preparedness in Bengaluru, India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.07.22276915
DO 10.1101/2022.07.07.22276915
A1 Harsha, Pulleri Kandi
A1 Pattabiraman, Chitra
A1 George, Anson Kunjumon
A1 J, Madhusudhan
A1 Mardikar, Saumitra
A1 Nazaar, Mudasir
A1 Adimoolam, Srivathsan
A1 A, Divya Priya
A1 Pitale, Jayee
A1 Nagarajan, Mahesh
A1 Sridharan, Srikant
A1 Kannan, Yasodha
A1 Janakiraman, Anand
A1 Veeramachaneni, Vamsi
A1 Hariharan, Ramesh
A1 Rao, Vishal US
A1 Shariff, Mohammed
A1 Chandra, Thrilok
A1 Sudhakar, K.
A1 Dev, Randeep
A1 Vasanthapuram, Ravi
A1 Chandru, Vijay
YR 2022
UL http://medrxiv.org/content/early/2022/07/09/2022.07.07.22276915.abstract
AB A comprehensive SARS-CoV-2 genomic surveillance programme that integrates logistics, laboratory work, bioinformatics, analytics, and timely reporting was deployed through a public-private partnership in the city of Bengaluru, Karnataka in India. As a result, 12461 samples have been sequenced and reported to the Karnataka State public health officials as time-sensitive, decision support during the last one year and uploaded in global public databases in a timely manner. This programme has developed an analytics platform for studying SARS-CoV-2 sequences and their epidemiological context. Continuous sequencing effort enabled timely detection of emergence of Omicron variant in India and the subsequent spread of the same and its sub-lineages with more logistic growth (BA.10, BA.12 and BA.5) in Bengaluru. Our data also helped to provide timely information on variants to determine which of the Variants of Concern tracked globally, were observed in Bengaluru, ensuring targeted efforts and reducing unwarranted fear. This effort highlights the importance of, and the urgent need to, increase genomic surveillance to support the states with limited sequencing and bioinformatics capacity. We describe the development and deployment of this end-to-end solution for genomic surveillance of SARS-CoV-2 in the city of Bengaluru.Competing Interest StatementAuthors who are employees of Strand Life Sciences Private Limited may hold shares in Strand Life Sciences Private Limited. The remaining authors declare no competing interests.Clinical Protocols https://simplifiedupsc.in/insacog/ Funding StatementThe study was funded by several philanthropies - primarily IN COVID Support via ACT Grants; Give India and United Way.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Committee at HCG (Health Care Global) reviewed our study and approved the study. Also, the Covid Task Force, Govt of Karnataka and State genomic surveillance committee provided approvals.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://www.gisaid.org/ The Global Initiative on Sharing Avian Influenza Data has become the defacto global portal for the genomic sequences of SARS-CoV2. https://www.gisaid.org/